Purchase this article with an account.
Pia Allegri, Ugo Murialdo, Simona Peri, Rosanna Carniglia, Maria Grazia Crivelli, Silvia Compiano, Silvia Autuori, Antonio Mastromarino, Monia Zurria, Giuseppina Marrazzo; Randomized, Double-Blind, Placebo-Controlled Clinical Trial on the Efficacy of 0.5% Indomethacin Eye Drops in Uveitic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2014;55(3):1463-1470. doi: 10.1167/iovs.13-13202.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The aim of the present randomized, double-blind, placebo-controlled clinical trial was to assess the efficacy and tolerability of 0.5% indomethacin (INDOM) eye drops in adult patients suffering from macular edema (ME) related to different etiology uveitis.
Forty-six eyes of 31 adult patients (20 females and 11 males) mean age 39 years, affected by inflammatory ME, were randomized to receive a dose of commercial 0.5% INDOM eye-drops four times per day (16 subjects = 23 eyes) or placebo (the vehicle of INDOM, 15 subjects = 23 eyes) during a 6-month active therapy follow-up. Study assessment at each visit included visual acuity testing (VA), slit-lamp examination, IOP evaluation, and Heidelberg Spectralis optical coherence tomography (OCT) central foveal thickness (CFT) measurement. Any variation in subjective symptoms and tolerability was also detected.
Statistical analysis showed, from baseline to the 6-month visit, a significant reduction in CFT (P < 0.0001) and a significant improvement in VA only in the 0.5% INDOM-treated group; a global reduction of discomfort symptoms was present in both groups (P < 0.001).
The four times per day administration of 0.5% INDOM eye drops in eyes affected with uveitic ME from different etiologies, compared with placebo, is associated with a significant reduction in ME at the 6-month follow-up visit, as measured by spectral-domain optical coherence tomography (SD-OCT). However, not all eyes showed a complete resolution of ME because of vitreoretinal traction. ( https://eudract.ema.europa.eu/index.html number, EUDRACT 2011-001522-20.)
This PDF is available to Subscribers Only